Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study

    ... BACKGROUND: Myelodysplastic syndromes are characterised by ineffective erythropoiesis. Luspatercept ...

    Research Article last updated 09/18/2017 - 1:38pm.

  2. Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R

    ... (NGS) in 179 patients (median age 73 years) with primary myelodysplastic syndromes (MDS); risk distribution according to the revised ...

    Research Article last updated 09/18/2017 - 11:05am.

  3. The Challenge of Treating Myelodysplastic Syndromes/Myeloproliferative Neoplasms.

    ... July 15, 2017 Myelodysplastic syndromes /myeloproliferative neoplasms (MDS/MPN) comprise a spectrum of ...

    Research Article last updated 09/11/2017 - 8:45am.

  4. Early treatment initiation in lower-risk myelodysplastic syndromes produces an earlier and higher rate of transfusion independence

    ... August 1, 2017 Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis ...

    Research Article last updated 09/13/2017 - 8:58am.

  5. The microenvironment in myelodysplastic syndromes: niche-mediated disease initiation and progression

    ... August 18, 2017 Myelodysplastic syndromes (MDS) are clonal disorders of hematopoietic stem and progenitor ...

    Research Article last updated 09/13/2017 - 8:25am.

  6. A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials.

    ... landscape of the management of patients with higher-risk myelodysplastic syndromes (HR-MDS). HMAs have improved hematopoiesis and quality of ...

    Research Article last updated 09/11/2017 - 9:04am.

  7. Progress in Myelodysplastic Syndromes: Clinicopathologic Correlations and Immune Checkpoints

    ... BACKGROUND: Myelodysplastic syndromes (MDS) are a group of clonal neoplasms characterized by ...

    Research Article last updated 09/11/2017 - 8:59am.

  8. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond

    ... September 16, 2017 Myelodysplastic syndrome (MDS) with deletion 5q (del(5q)) is a distinct ... Bone Marrow Diseases:  myelodysplastic syndromes (MDS) ...

    Research Article last updated 10/02/2017 - 9:54am.

  9. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond

    ... June 22, 2017 Myelodysplastic syndrome (MDS) with deletion 5q (del(5q)) is a distinct ...

    Research Article last updated 10/23/2017 - 10:58am.

  10. Differences in genomic patterns and clinical outcomes between African-American and White patients with myelodysplastic syndromes

    ... Bone Marrow Diseases:  myelodysplastic syndromes (MDS) ...

    Research Article last updated 09/18/2017 - 2:37pm.